CERENO SCIENTIFIC Aktie

 

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company is added to the First North 25™ Index (FN25 Index). The Index gathers a selection of the largest and most traded securities on the Nasdaq Nordic First North Growth Markets. The inclusion is effective at market open on Tuesday, July 1, 2025. "Being included in the First North 25 Index is a proud milestone for Cereno Scientific and a reflection of the progress we have made in building...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the top-line results of CS014's Phase I trial will be announced mid-July 2025. The previously communicated timeline was June 2025. The Phase I trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. "The first-in-human Phase I trial of CS014 was successfully conducted and...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced entering loan financing agreements securing a total of 100 MSEK. The financing is achieved through an addendum (the “Addendum”) to the loan financing agreement (the “Original Financing Agreement”) entered in November 2024 with Fenja Capital II A/S and the US-based investor Arena Investors, LP (the “Original Financiers”) and additionally entering into a new loan agreement (the “New Financing Agreement”)...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced 4-month follow-up data from the Expanded Access Program (EAP) following the Phase IIa trial of CS1 in patients with pulmonary arterial hypertension (PAH). The 4-month data from the EAP is in line with the observations made in the Phase IIa trial. Drug candidate CS1, an epigenetic modulating HDAC-inhibitor, has a strong potential to transform the lives of PAH patients as a well-tolerated oral therapy...

Today, June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairman of the Annual General Meeting (the “AGM”) was Eric Ehrencrona, lawyer and partner at MAQS Advokatbyrå. The following main resolutions were resolved upon at the AGM: Adoption of income statement and balance sheet for the company and the group The AGM resolved to adopt the presented income statement and balance sheet for the company and the group. Allocation of result The AGM resolved, in accordance with the Board of...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company has been nominated for the 'Company of the Year' award at the European Mediscience Awards 2025. The prestigious European Mediscience Awards is the largest annual gathering showcasing achievement and success in the UK and European healthcare, biotech, pharmaceutical and life sciences sectors. The European Mediscience Awards 2025 will take place on June 12, at the Hotel InterContinental...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the US Food & Drug Administration (FDA) provided endorsement of the plans for the Phase IIb trial of CS1 as noted by the official meeting minutes from the Type C-meeting held on April 21. The next clinical development step of CS1 is a larger, placebo-controlled Phase IIb trial aiming to further evaluate the encouraging efficacy signs including reverse vascular remodeling and improvement of right...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Board of Directors and Chief Executive Officer of Cereno Scientific AB here presents the Interim Report for Q1 2025 (January 1 – March 31). Financial overview Cereno Scientific Group – Q1 · Net Sales were SEK 0 (0) · Result after financial items was SEK -25 009 234 (-15 437 724) · Earnings per share was SEK -0.09 (-0.07) before dilution and SEK -0.08 (-0.05) after dilution ·...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Annual Report for 2024 is published. The Annual Report is now available digitally in English and Swedish at www.cerenoscientific.com/investors.   For further information, please contact: Tove Bergenholt, Head of IR & Communications Email:  tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46     About Cereno Scientific AB Cereno Scientific is pioneering...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that an oral presentation titled “Exploratory outcomes of CS1 in Pulmonary Arterial Hypertension: Phase 2A, Prospective, Randomized, Open-Label, Multicenter Trial” was presented at the 5th Baltic Pulmonary Hypertension Conference 2025 on May 9, 2025, in Kaunas, Lithuania. The data presented in an abstract at the Baltic PH Conference highlighted key results from the Phase IIa trial of CS1 in PAH.  The...

The shareholders of Cereno Scientific AB (publ), company registration no. 556890-4071, (the “Company”) are hereby given notice to attend the Annual General Meeting to be held on Tuesday 10 June 2025 at 11 a.m. at MAQS Advokatbyrå's premises, at the address Masthamnsgatan 13 in Gothenburg (please note this is a new address compared to previously). Registration for the Annual General Meeting will commence at 10.30 a.m. Registration of attendance at the Annual General Meeting will be cancelled when the general meeting opens.   Right to participate at the Annual General Meeting Any...

Correction: Thie previous press release stated the wrong date for the Annual General Meeting 2025.  The Nomination Committee of Cereno Scientific AB (publ) (the “Company”) has today decided to propose a new Board of Directors at the Annual General Meeting on June 10, 2025, with particular expertise in M&A/partnering and business development (BD). The Nomination Committee's proposal means that Jeppe Øvlesen is proposed as the new Chairman of the Board, that Moi Brajanovic is proposed to be newly elected as a Board member and that Joakim Söderström is not proposed to be a member of the Board....

The Nomination Committee of Cereno Scientific AB (publ) (the “Company”) has today decided to propose a new Board of Directors at the Annual General Meeting on June 10, 2025, with particular expertise in M&A/partnering and business development (BD). The Nomination Committee's proposal means that Jeppe Øvlesen is proposed as the new Chairman of the Board, that Moi Brajanovic is proposed to be newly elected as a Board member and that Joakim Söderström is not proposed to be a member of the Board. The other Board members Anders Svensson, Gunnar Olsson and Sten R. Sörensen are proposed to be re-...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will present at the ABGSC Investor Days held on May 13-14, 2025, in Stockholm. Sten R. Sörensen, CEO, will present on Tuesday, May 13, at 16:00 in “Track 1.” The ABGSC Investor Days is held on May 13-14 at Hotel At Six, Brunkebergstorg 6 in Stockholm. The presentations will be live streamed and will also be available after the event on ABGSC and Cereno's websites. More information...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will be participating at the annual partnering conference LSX Nordics on May 20-21, 2025, in Bergen, Norway. The LSX Nordics conference is the leading partnering and investment event in the Nordic and Baltic region. “At Cereno Scientific, we are having a very busy spring as we are pursuing a multitude of key milestones for our drug development programs. We have so far showcased our...

Cereno Scientific has taken another important step forward with lead candidate CS1. Yesterday, the Swedish biotech held a constructive Type C meeting with the U.S. Food and Drug Administration. The discussions suggest alignment between Cereno Scientific and the FDA on the development path. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/04/cereno-scientific-aligns-with-fda-on-cs1-development/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company has completed a Type C meeting with the U.S. Food and Drug Administration (FDA). The intention was to seek advice from the FDA to finalize the Phase IIb trial design and align on further clinical development steps for CS1 based on the encouraging signals suggesting reverse vascular remodeling effects observed in the Phase IIa trial. The discussions during the meeting indicate...

Cereno Scientific announced today the successful completion of the second and final part of its phase I clinical trial evaluating drug candidate CS014 in healthy volunteers. The milestone was marked by the last patient's last visit, and top-line results are expected in June 2025. Read the article at biostock.se: https://www.biostock.se/en/2025/04/cereno-completes-cs014-trial-ahead-of-june-top-line-data/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the second and final part of the Phase I trial of drug candidate CS014 in healthy volunteers has been concluded with the last patient's last visit. The Phase I trial intends to primarily evaluate the safety and tolerability profile of CS014 in humans and is divided into two parts – a single ascending dose part (SAD) and a multiple ascending dose part (MAD). Data management, database lock, and...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that it will be attending the annual partnering conference BIO International Convention on June 16-19, 2025, in Boston, US. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. “BIO 2025 in Boston serves as a pivotal platform for fostering strategic partnerships...